Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 1;34(1):89-94.
doi: 10.1097/CCO.0000000000000800.

Novel immunotherapeutic drugs for the treatment of lung cancer

Ling Peng  1 , Zibing Wang  2 , Justin Stebbing  3 , Zhentao Yu  4
Affiliations
Review

Novel immunotherapeutic drugs for the treatment of lung cancer

Ling Peng et al. Curr Opin Oncol. .

Abstract

Purpose of review: Cancer cells evade immune surveillance partly due to the immunosuppressive features of the tumor microenvironment (TME). Currently approved immuno-oncology drugs for the treatment of lung cancer are aimed to inhibit immune checkpoints, such as programmed death protein-1 (PD-1), PD ligand-1 (PD-L1) and cytotoxic T lymphocyte-associated antigen 4. Despite these, researchers are currently racing to create the optimal cancer immunotherapy treatments.

Recent findings: Novel immunotherapeutic drugs mainly act on activated immune cells and exert their therapeutic effects by enhancing antitumor responses. In this article, we review new therapies for the treatment of lung cancer that enhance T cell priming, remove coinhibitory signals, supply costimulatory signals and condition the TME.

Summary: As more immunotherapeutic targets are in studies, designing multimodal strategies to provide greater efficacy with lower toxicity will be necessary.

PubMed Disclaimer

References

    1. Yao S, Zhu Y, Chen L. Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov 2013; 12:130–146.
    1. Whiteside TL, Demaria S, Rodriguez-Ruiz ME, et al. Emerging opportunities and challenges in cancer immunotherapy. Clin Cancer Res 2016; 22:1845–1855.
    1. Goldberg MV, Drake CG. LAG-3 in cancer immunotherapy. Curr Top Microbiol Immunol 2011; 344:269–278.
    1. Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation. Immunity 2016; 44:989–1004.
    1. Yu X, Huang X, Chen X, et al. Characterization of a novel antihuman lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy. MAbs 2019; 11:1139–1148.